- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
According to our latest study, the global Pharmaceutical CDMO market size was valued at USD 131990 million in 2022 and is forecast to a readjusted size of USD 216840 million by 2029 with a CAGR of 7.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.
Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.
This report is a detailed and comprehensive analysis for global Pharmaceutical CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Pharmaceutical CDMO market size and forecasts, in consumption value ($ Million), 2018-2029
Global Pharmaceutical CDMO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Pharmaceutical CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Pharmaceutical CDMO market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pharmaceutical CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pharmaceutical CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics and Fareva, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Pharmaceutical CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Market segment by players, this report covers
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pharmaceutical CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pharmaceutical CDMO, with revenue, gross margin and global market share of Pharmaceutical CDMO from 2018 to 2023.
Chapter 3, the Pharmaceutical CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Pharmaceutical CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Pharmaceutical CDMO.
Chapter 13, to describe Pharmaceutical CDMO research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Pharmaceutical CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Pharmaceutical CDMO by Type
1.3.1 Overview: Global Pharmaceutical CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Pharmaceutical CDMO Consumption Value Market Share by Type in 2022
1.3.3 API CDMO
1.3.4 FDF CDMO
1.3.5 Packaging CDMO
1.3.6 Clinical CDMO
1.4 Global Pharmaceutical CDMO Market by Application
1.4.1 Overview: Global Pharmaceutical CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Pharmaceutical Company
1.4.3 Biotechnology Company
1.4.4 Other
1.5 Global Pharmaceutical CDMO Market Size & Forecast
1.6 Global Pharmaceutical CDMO Market Size and Forecast by Region
1.6.1 Global Pharmaceutical CDMO Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Pharmaceutical CDMO Market Size by Region, (2018-2029)
1.6.3 North America Pharmaceutical CDMO Market Size and Prospect (2018-2029)
1.6.4 Europe Pharmaceutical CDMO Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Pharmaceutical CDMO Market Size and Prospect (2018-2029)
1.6.6 South America Pharmaceutical CDMO Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Pharmaceutical CDMO Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Pharmaceutical CDMO Product and Solutions
2.1.4 Lonza Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Lonza Recent Developments and Future Plans
2.2 Catalent
2.2.1 Catalent Details
2.2.2 Catalent Major Business
2.2.3 Catalent Pharmaceutical CDMO Product and Solutions
2.2.4 Catalent Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Catalent Recent Developments and Future Plans
2.3 Thermo Fisher Scientific
2.3.1 Thermo Fisher Scientific Details
2.3.2 Thermo Fisher Scientific Major Business
2.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Product and Solutions
2.3.4 Thermo Fisher Scientific Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.4 Samsung Biologics
2.4.1 Samsung Biologics Details
2.4.2 Samsung Biologics Major Business
2.4.3 Samsung Biologics Pharmaceutical CDMO Product and Solutions
2.4.4 Samsung Biologics Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Samsung Biologics Recent Developments and Future Plans
2.5 Fareva
2.5.1 Fareva Details
2.5.2 Fareva Major Business
2.5.3 Fareva Pharmaceutical CDMO Product and Solutions
2.5.4 Fareva Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Fareva Recent Developments and Future Plans
2.6 WuXi AppTech
2.6.1 WuXi AppTech Details
2.6.2 WuXi AppTech Major Business
2.6.3 WuXi AppTech Pharmaceutical CDMO Product and Solutions
2.6.4 WuXi AppTech Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 WuXi AppTech Recent Developments and Future Plans
2.7 WuXi Biologics
2.7.1 WuXi Biologics Details
2.7.2 WuXi Biologics Major Business
2.7.3 WuXi Biologics Pharmaceutical CDMO Product and Solutions
2.7.4 WuXi Biologics Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 WuXi Biologics Recent Developments and Future Plans
2.8 Siegfried
2.8.1 Siegfried Details
2.8.2 Siegfried Major Business
2.8.3 Siegfried Pharmaceutical CDMO Product and Solutions
2.8.4 Siegfried Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Siegfried Recent Developments and Future Plans
2.9 FUJIFILM Diosynth Biotechnologies
2.9.1 FUJIFILM Diosynth Biotechnologies Details
2.9.2 FUJIFILM Diosynth Biotechnologies Major Business
2.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product and Solutions
2.9.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.10 Asymchem
2.10.1 Asymchem Details
2.10.2 Asymchem Major Business
2.10.3 Asymchem Pharmaceutical CDMO Product and Solutions
2.10.4 Asymchem Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Asymchem Recent Developments and Future Plans
2.11 Pfizer CentreOne
2.11.1 Pfizer CentreOne Details
2.11.2 Pfizer CentreOne Major Business
2.11.3 Pfizer CentreOne Pharmaceutical CDMO Product and Solutions
2.11.4 Pfizer CentreOne Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Pfizer CentreOne Recent Developments and Future Plans
2.12 Delpharm
2.12.1 Delpharm Details
2.12.2 Delpharm Major Business
2.12.3 Delpharm Pharmaceutical CDMO Product and Solutions
2.12.4 Delpharm Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Delpharm Recent Developments and Future Plans
2.13 Recipharm
2.13.1 Recipharm Details
2.13.2 Recipharm Major Business
2.13.3 Recipharm Pharmaceutical CDMO Product and Solutions
2.13.4 Recipharm Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Recipharm Recent Developments and Future Plans
2.14 AGC Pharma Chemicals
2.14.1 AGC Pharma Chemicals Details
2.14.2 AGC Pharma Chemicals Major Business
2.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Product and Solutions
2.14.4 AGC Pharma Chemicals Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 AGC Pharma Chemicals Recent Developments and Future Plans
2.15 Boehringer Ingelheim
2.15.1 Boehringer Ingelheim Details
2.15.2 Boehringer Ingelheim Major Business
2.15.3 Boehringer Ingelheim Pharmaceutical CDMO Product and Solutions
2.15.4 Boehringer Ingelheim Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Boehringer Ingelheim Recent Developments and Future Plans
2.16 Vetter
2.16.1 Vetter Details
2.16.2 Vetter Major Business
2.16.3 Vetter Pharmaceutical CDMO Product and Solutions
2.16.4 Vetter Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Vetter Recent Developments and Future Plans
2.17 Curia
2.17.1 Curia Details
2.17.2 Curia Major Business
2.17.3 Curia Pharmaceutical CDMO Product and Solutions
2.17.4 Curia Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Curia Recent Developments and Future Plans
2.18 Aenova
2.18.1 Aenova Details
2.18.2 Aenova Major Business
2.18.3 Aenova Pharmaceutical CDMO Product and Solutions
2.18.4 Aenova Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Aenova Recent Developments and Future Plans
2.19 Porton
2.19.1 Porton Details
2.19.2 Porton Major Business
2.19.3 Porton Pharmaceutical CDMO Product and Solutions
2.19.4 Porton Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Porton Recent Developments and Future Plans
2.20 Piramal
2.20.1 Piramal Details
2.20.2 Piramal Major Business
2.20.3 Piramal Pharmaceutical CDMO Product and Solutions
2.20.4 Piramal Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Piramal Recent Developments and Future Plans
2.21 Strides Pharma
2.21.1 Strides Pharma Details
2.21.2 Strides Pharma Major Business
2.21.3 Strides Pharma Pharmaceutical CDMO Product and Solutions
2.21.4 Strides Pharma Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 Strides Pharma Recent Developments and Future Plans
2.22 NextPharma
2.22.1 NextPharma Details
2.22.2 NextPharma Major Business
2.22.3 NextPharma Pharmaceutical CDMO Product and Solutions
2.22.4 NextPharma Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 NextPharma Recent Developments and Future Plans
2.23 Famar
2.23.1 Famar Details
2.23.2 Famar Major Business
2.23.3 Famar Pharmaceutical CDMO Product and Solutions
2.23.4 Famar Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.23.5 Famar Recent Developments and Future Plans
2.24 Jubilant
2.24.1 Jubilant Details
2.24.2 Jubilant Major Business
2.24.3 Jubilant Pharmaceutical CDMO Product and Solutions
2.24.4 Jubilant Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.24.5 Jubilant Recent Developments and Future Plans
2.25 Alcami
2.25.1 Alcami Details
2.25.2 Alcami Major Business
2.25.3 Alcami Pharmaceutical CDMO Product and Solutions
2.25.4 Alcami Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.25.5 Alcami Recent Developments and Future Plans
2.26 Euroapi
2.26.1 Euroapi Details
2.26.2 Euroapi Major Business
2.26.3 Euroapi Pharmaceutical CDMO Product and Solutions
2.26.4 Euroapi Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.26.5 Euroapi Recent Developments and Future Plans
2.27 Eurofins
2.27.1 Eurofins Details
2.27.2 Eurofins Major Business
2.27.3 Eurofins Pharmaceutical CDMO Product and Solutions
2.27.4 Eurofins Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.27.5 Eurofins Recent Developments and Future Plans
2.28 Avid Bioservices
2.28.1 Avid Bioservices Details
2.28.2 Avid Bioservices Major Business
2.28.3 Avid Bioservices Pharmaceutical CDMO Product and Solutions
2.28.4 Avid Bioservices Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.28.5 Avid Bioservices Recent Developments and Future Plans
2.29 BioVectra
2.29.1 BioVectra Details
2.29.2 BioVectra Major Business
2.29.3 BioVectra Pharmaceutical CDMO Product and Solutions
2.29.4 BioVectra Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.29.5 BioVectra Recent Developments and Future Plans
2.30 CPL
2.30.1 CPL Details
2.30.2 CPL Major Business
2.30.3 CPL Pharmaceutical CDMO Product and Solutions
2.30.4 CPL Pharmaceutical CDMO Revenue, Gross Margin and Market Share (2018-2023)
2.30.5 CPL Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Pharmaceutical CDMO Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Pharmaceutical CDMO by Company Revenue
3.2.2 Top 3 Pharmaceutical CDMO Players Market Share in 2022
3.2.3 Top 6 Pharmaceutical CDMO Players Market Share in 2022
3.3 Pharmaceutical CDMO Market: Overall Company Footprint Analysis
3.3.1 Pharmaceutical CDMO Market: Region Footprint
3.3.2 Pharmaceutical CDMO Market: Company Product Type Footprint
3.3.3 Pharmaceutical CDMO Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Pharmaceutical CDMO Consumption Value and Market Share by Type (2018-2023)
4.2 Global Pharmaceutical CDMO Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Pharmaceutical CDMO Consumption Value Market Share by Application (2018-2023)
5.2 Global Pharmaceutical CDMO Market Forecast by Application (2024-2029)
6 North America
6.1 North America Pharmaceutical CDMO Consumption Value by Type (2018-2029)
6.2 North America Pharmaceutical CDMO Consumption Value by Application (2018-2029)
6.3 North America Pharmaceutical CDMO Market Size by Country
6.3.1 North America Pharmaceutical CDMO Consumption Value by Country (2018-2029)
6.3.2 United States Pharmaceutical CDMO Market Size and Forecast (2018-2029)
6.3.3 Canada Pharmaceutical CDMO Market Size and Forecast (2018-2029)
6.3.4 Mexico Pharmaceutical CDMO Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Pharmaceutical CDMO Consumption Value by Type (2018-2029)
7.2 Europe Pharmaceutical CDMO Consumption Value by Application (2018-2029)
7.3 Europe Pharmaceutical CDMO Market Size by Country
7.3.1 Europe Pharmaceutical CDMO Consumption Value by Country (2018-2029)
7.3.2 Germany Pharmaceutical CDMO Market Size and Forecast (2018-2029)
7.3.3 France Pharmaceutical CDMO Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Pharmaceutical CDMO Market Size and Forecast (2018-2029)
7.3.5 Russia Pharmaceutical CDMO Market Size and Forecast (2018-2029)
7.3.6 Italy Pharmaceutical CDMO Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Pharmaceutical CDMO Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Pharmaceutical CDMO Market Size by Region
8.3.1 Asia-Pacific Pharmaceutical CDMO Consumption Value by Region (2018-2029)
8.3.2 China Pharmaceutical CDMO Market Size and Forecast (2018-2029)
8.3.3 Japan Pharmaceutical CDMO Market Size and Forecast (2018-2029)
8.3.4 South Korea Pharmaceutical CDMO Market Size and Forecast (2018-2029)
8.3.5 India Pharmaceutical CDMO Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Pharmaceutical CDMO Market Size and Forecast (2018-2029)
8.3.7 Australia Pharmaceutical CDMO Market Size and Forecast (2018-2029)
9 South America
9.1 South America Pharmaceutical CDMO Consumption Value by Type (2018-2029)
9.2 South America Pharmaceutical CDMO Consumption Value by Application (2018-2029)
9.3 South America Pharmaceutical CDMO Market Size by Country
9.3.1 South America Pharmaceutical CDMO Consumption Value by Country (2018-2029)
9.3.2 Brazil Pharmaceutical CDMO Market Size and Forecast (2018-2029)
9.3.3 Argentina Pharmaceutical CDMO Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Pharmaceutical CDMO Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Pharmaceutical CDMO Market Size by Country
10.3.1 Middle East & Africa Pharmaceutical CDMO Consumption Value by Country (2018-2029)
10.3.2 Turkey Pharmaceutical CDMO Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Pharmaceutical CDMO Market Size and Forecast (2018-2029)
10.3.4 UAE Pharmaceutical CDMO Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Pharmaceutical CDMO Market Drivers
11.2 Pharmaceutical CDMO Market Restraints
11.3 Pharmaceutical CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Pharmaceutical CDMO Industry Chain
12.2 Pharmaceutical CDMO Upstream Analysis
12.3 Pharmaceutical CDMO Midstream Analysis
12.4 Pharmaceutical CDMO Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Pharmaceutical CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Pharmaceutical CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Pharmaceutical CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Pharmaceutical CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Lonza Company Information, Head Office, and Major Competitors
Table 6. Lonza Major Business
Table 7. Lonza Pharmaceutical CDMO Product and Solutions
Table 8. Lonza Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Lonza Recent Developments and Future Plans
Table 10. Catalent Company Information, Head Office, and Major Competitors
Table 11. Catalent Major Business
Table 12. Catalent Pharmaceutical CDMO Product and Solutions
Table 13. Catalent Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Catalent Recent Developments and Future Plans
Table 15. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 16. Thermo Fisher Scientific Major Business
Table 17. Thermo Fisher Scientific Pharmaceutical CDMO Product and Solutions
Table 18. Thermo Fisher Scientific Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Thermo Fisher Scientific Recent Developments and Future Plans
Table 20. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 21. Samsung Biologics Major Business
Table 22. Samsung Biologics Pharmaceutical CDMO Product and Solutions
Table 23. Samsung Biologics Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Samsung Biologics Recent Developments and Future Plans
Table 25. Fareva Company Information, Head Office, and Major Competitors
Table 26. Fareva Major Business
Table 27. Fareva Pharmaceutical CDMO Product and Solutions
Table 28. Fareva Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Fareva Recent Developments and Future Plans
Table 30. WuXi AppTech Company Information, Head Office, and Major Competitors
Table 31. WuXi AppTech Major Business
Table 32. WuXi AppTech Pharmaceutical CDMO Product and Solutions
Table 33. WuXi AppTech Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. WuXi AppTech Recent Developments and Future Plans
Table 35. WuXi Biologics Company Information, Head Office, and Major Competitors
Table 36. WuXi Biologics Major Business
Table 37. WuXi Biologics Pharmaceutical CDMO Product and Solutions
Table 38. WuXi Biologics Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. WuXi Biologics Recent Developments and Future Plans
Table 40. Siegfried Company Information, Head Office, and Major Competitors
Table 41. Siegfried Major Business
Table 42. Siegfried Pharmaceutical CDMO Product and Solutions
Table 43. Siegfried Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Siegfried Recent Developments and Future Plans
Table 45. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors
Table 46. FUJIFILM Diosynth Biotechnologies Major Business
Table 47. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Product and Solutions
Table 48. FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
Table 50. Asymchem Company Information, Head Office, and Major Competitors
Table 51. Asymchem Major Business
Table 52. Asymchem Pharmaceutical CDMO Product and Solutions
Table 53. Asymchem Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Asymchem Recent Developments and Future Plans
Table 55. Pfizer CentreOne Company Information, Head Office, and Major Competitors
Table 56. Pfizer CentreOne Major Business
Table 57. Pfizer CentreOne Pharmaceutical CDMO Product and Solutions
Table 58. Pfizer CentreOne Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Pfizer CentreOne Recent Developments and Future Plans
Table 60. Delpharm Company Information, Head Office, and Major Competitors
Table 61. Delpharm Major Business
Table 62. Delpharm Pharmaceutical CDMO Product and Solutions
Table 63. Delpharm Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Delpharm Recent Developments and Future Plans
Table 65. Recipharm Company Information, Head Office, and Major Competitors
Table 66. Recipharm Major Business
Table 67. Recipharm Pharmaceutical CDMO Product and Solutions
Table 68. Recipharm Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Recipharm Recent Developments and Future Plans
Table 70. AGC Pharma Chemicals Company Information, Head Office, and Major Competitors
Table 71. AGC Pharma Chemicals Major Business
Table 72. AGC Pharma Chemicals Pharmaceutical CDMO Product and Solutions
Table 73. AGC Pharma Chemicals Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. AGC Pharma Chemicals Recent Developments and Future Plans
Table 75. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 76. Boehringer Ingelheim Major Business
Table 77. Boehringer Ingelheim Pharmaceutical CDMO Product and Solutions
Table 78. Boehringer Ingelheim Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Boehringer Ingelheim Recent Developments and Future Plans
Table 80. Vetter Company Information, Head Office, and Major Competitors
Table 81. Vetter Major Business
Table 82. Vetter Pharmaceutical CDMO Product and Solutions
Table 83. Vetter Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Vetter Recent Developments and Future Plans
Table 85. Curia Company Information, Head Office, and Major Competitors
Table 86. Curia Major Business
Table 87. Curia Pharmaceutical CDMO Product and Solutions
Table 88. Curia Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Curia Recent Developments and Future Plans
Table 90. Aenova Company Information, Head Office, and Major Competitors
Table 91. Aenova Major Business
Table 92. Aenova Pharmaceutical CDMO Product and Solutions
Table 93. Aenova Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Aenova Recent Developments and Future Plans
Table 95. Porton Company Information, Head Office, and Major Competitors
Table 96. Porton Major Business
Table 97. Porton Pharmaceutical CDMO Product and Solutions
Table 98. Porton Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Porton Recent Developments and Future Plans
Table 100. Piramal Company Information, Head Office, and Major Competitors
Table 101. Piramal Major Business
Table 102. Piramal Pharmaceutical CDMO Product and Solutions
Table 103. Piramal Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. Piramal Recent Developments and Future Plans
Table 105. Strides Pharma Company Information, Head Office, and Major Competitors
Table 106. Strides Pharma Major Business
Table 107. Strides Pharma Pharmaceutical CDMO Product and Solutions
Table 108. Strides Pharma Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 109. Strides Pharma Recent Developments and Future Plans
Table 110. NextPharma Company Information, Head Office, and Major Competitors
Table 111. NextPharma Major Business
Table 112. NextPharma Pharmaceutical CDMO Product and Solutions
Table 113. NextPharma Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 114. NextPharma Recent Developments and Future Plans
Table 115. Famar Company Information, Head Office, and Major Competitors
Table 116. Famar Major Business
Table 117. Famar Pharmaceutical CDMO Product and Solutions
Table 118. Famar Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Famar Recent Developments and Future Plans
Table 120. Jubilant Company Information, Head Office, and Major Competitors
Table 121. Jubilant Major Business
Table 122. Jubilant Pharmaceutical CDMO Product and Solutions
Table 123. Jubilant Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 124. Jubilant Recent Developments and Future Plans
Table 125. Alcami Company Information, Head Office, and Major Competitors
Table 126. Alcami Major Business
Table 127. Alcami Pharmaceutical CDMO Product and Solutions
Table 128. Alcami Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 129. Alcami Recent Developments and Future Plans
Table 130. Euroapi Company Information, Head Office, and Major Competitors
Table 131. Euroapi Major Business
Table 132. Euroapi Pharmaceutical CDMO Product and Solutions
Table 133. Euroapi Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 134. Euroapi Recent Developments and Future Plans
Table 135. Eurofins Company Information, Head Office, and Major Competitors
Table 136. Eurofins Major Business
Table 137. Eurofins Pharmaceutical CDMO Product and Solutions
Table 138. Eurofins Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 139. Eurofins Recent Developments and Future Plans
Table 140. Avid Bioservices Company Information, Head Office, and Major Competitors
Table 141. Avid Bioservices Major Business
Table 142. Avid Bioservices Pharmaceutical CDMO Product and Solutions
Table 143. Avid Bioservices Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 144. Avid Bioservices Recent Developments and Future Plans
Table 145. BioVectra Company Information, Head Office, and Major Competitors
Table 146. BioVectra Major Business
Table 147. BioVectra Pharmaceutical CDMO Product and Solutions
Table 148. BioVectra Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 149. BioVectra Recent Developments and Future Plans
Table 150. CPL Company Information, Head Office, and Major Competitors
Table 151. CPL Major Business
Table 152. CPL Pharmaceutical CDMO Product and Solutions
Table 153. CPL Pharmaceutical CDMO Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 154. CPL Recent Developments and Future Plans
Table 155. Global Pharmaceutical CDMO Revenue (USD Million) by Players (2018-2023)
Table 156. Global Pharmaceutical CDMO Revenue Share by Players (2018-2023)
Table 157. Breakdown of Pharmaceutical CDMO by Company Type (Tier 1, Tier 2, and Tier 3)
Table 158. Market Position of Players in Pharmaceutical CDMO, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 159. Head Office of Key Pharmaceutical CDMO Players
Table 160. Pharmaceutical CDMO Market: Company Product Type Footprint
Table 161. Pharmaceutical CDMO Market: Company Product Application Footprint
Table 162. Pharmaceutical CDMO New Market Entrants and Barriers to Market Entry
Table 163. Pharmaceutical CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 164. Global Pharmaceutical CDMO Consumption Value (USD Million) by Type (2018-2023)
Table 165. Global Pharmaceutical CDMO Consumption Value Share by Type (2018-2023)
Table 166. Global Pharmaceutical CDMO Consumption Value Forecast by Type (2024-2029)
Table 167. Global Pharmaceutical CDMO Consumption Value by Application (2018-2023)
Table 168. Global Pharmaceutical CDMO Consumption Value Forecast by Application (2024-2029)
Table 169. North America Pharmaceutical CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 170. North America Pharmaceutical CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 171. North America Pharmaceutical CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 172. North America Pharmaceutical CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 173. North America Pharmaceutical CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 174. North America Pharmaceutical CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 175. Europe Pharmaceutical CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 176. Europe Pharmaceutical CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 177. Europe Pharmaceutical CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 178. Europe Pharmaceutical CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 179. Europe Pharmaceutical CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 180. Europe Pharmaceutical CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 181. Asia-Pacific Pharmaceutical CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 182. Asia-Pacific Pharmaceutical CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 183. Asia-Pacific Pharmaceutical CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 184. Asia-Pacific Pharmaceutical CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 185. Asia-Pacific Pharmaceutical CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 186. Asia-Pacific Pharmaceutical CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 187. South America Pharmaceutical CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 188. South America Pharmaceutical CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 189. South America Pharmaceutical CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 190. South America Pharmaceutical CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 191. South America Pharmaceutical CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 192. South America Pharmaceutical CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 193. Middle East & Africa Pharmaceutical CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 194. Middle East & Africa Pharmaceutical CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 195. Middle East & Africa Pharmaceutical CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 196. Middle East & Africa Pharmaceutical CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 197. Middle East & Africa Pharmaceutical CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 198. Middle East & Africa Pharmaceutical CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 199. Pharmaceutical CDMO Raw Material
Table 200. Key Suppliers of Pharmaceutical CDMO Raw Materials
List of Figures
Figure 1. Pharmaceutical CDMO Picture
Figure 2. Global Pharmaceutical CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Pharmaceutical CDMO Consumption Value Market Share by Type in 2022
Figure 4. API CDMO
Figure 5. FDF CDMO
Figure 6. Packaging CDMO
Figure 7. Clinical CDMO
Figure 8. Global Pharmaceutical CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Pharmaceutical CDMO Consumption Value Market Share by Application in 2022
Figure 10. Pharmaceutical Company Picture
Figure 11. Biotechnology Company Picture
Figure 12. Other Picture
Figure 13. Global Pharmaceutical CDMO Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Pharmaceutical CDMO Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Pharmaceutical CDMO Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Pharmaceutical CDMO Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Pharmaceutical CDMO Consumption Value Market Share by Region in 2022
Figure 18. North America Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Pharmaceutical CDMO Revenue Share by Players in 2022
Figure 24. Pharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Pharmaceutical CDMO Market Share in 2022
Figure 26. Global Top 6 Players Pharmaceutical CDMO Market Share in 2022
Figure 27. Global Pharmaceutical CDMO Consumption Value Share by Type (2018-2023)
Figure 28. Global Pharmaceutical CDMO Market Share Forecast by Type (2024-2029)
Figure 29. Global Pharmaceutical CDMO Consumption Value Share by Application (2018-2023)
Figure 30. Global Pharmaceutical CDMO Market Share Forecast by Application (2024-2029)
Figure 31. North America Pharmaceutical CDMO Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Pharmaceutical CDMO Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Pharmaceutical CDMO Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Pharmaceutical CDMO Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Pharmaceutical CDMO Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Pharmaceutical CDMO Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 41. France Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Pharmaceutical CDMO Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Pharmaceutical CDMO Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Pharmaceutical CDMO Consumption Value Market Share by Region (2018-2029)
Figure 48. China Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 51. India Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Pharmaceutical CDMO Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Pharmaceutical CDMO Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Pharmaceutical CDMO Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Pharmaceutical CDMO Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Pharmaceutical CDMO Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Pharmaceutical CDMO Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Pharmaceutical CDMO Consumption Value (2018-2029) & (USD Million)
Figure 65. Pharmaceutical CDMO Market Drivers
Figure 66. Pharmaceutical CDMO Market Restraints
Figure 67. Pharmaceutical CDMO Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Pharmaceutical CDMO in 2022
Figure 70. Manufacturing Process Analysis of Pharmaceutical CDMO
Figure 71. Pharmaceutical CDMO Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
